Search

Your search keyword '"Bouvaist H"' showing total 160 results
Start Over Author "Bouvaist H" Publication Year Range Last 10 years
160 results on '"Bouvaist H"'

1. Impact of a centre and home-based cardiac rehabilitation program on the quality of life of teenagers and young adults with congenital heart disease: The QUALIREHAB randomized controlled trial

Author

Amédro, P., primary, Gavotto, A., additional, Huguet, H., additional, Souilla, L., additional, Dauphin, C., additional, Dulac, Y., additional, Bouvaist, H., additional, Ovaert, C., additional, Combes, N., additional, Thambo, J.-B., additional, Bonnet, D., additional, Ansquer, H., additional, Cohen, L., additional, Hascoët, S., additional, Picot, M.-C., additional, and Guillaumont, S., additional

Published
2024
Full Text
View/download PDF

8. Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2

Author

Mavromanoli, A.C., Barco, S., Ageno, W., Bouvaist, H., Brodmann, M., Cuccia, C., Couturaud, F., Dellas, C., Dimopoulos, K., Duerschmied, D., Empen, K., Faggiano, P., Ferrari, E., Galie, N., Galvani, M., Ghuysen, A., Giannakoulas, G., Huisman, M.V., Jimenez, D., Kozak, M., Lang, I.M., Meneveau, N., Munzel, T., Palazzini, M., Petris, A.O., Piovaccari, G., Salvi, A., Schellong, S., Schmidt, K.H., Verschuren, F., Schmidtmann, I., Toenges, G., Klok, F.A., Konstantinides, S.V., and PEITHO-2 Investigators

Subjects
Science & Technology, Cardiac & Cardiovascular Systems, Pulmonary embolism, WORKING GROUP, General Medicine, ASSOCIATION, GUIDELINES, EUROPEAN-SOCIETY, DYSFUNCTION, Echocardiography, Dysfunction, Cardiovascular System & Cardiology, MANAGEMENT, HEART, Right ventricle, Intermediate-risk, Cardiology and Cardiovascular Medicine, FOLLOW-UP, Life Sciences & Biomedicine, CARDIOLOGY
Abstract

Background Right ventricular (RV) function plays a critical role in the pathophysiology and acute prognosis of pulmonary embolism (PE). We analyzed the temporal changes of RV function in the cohort of a prospective multicentre study investigating if an early switch to oral anticoagulation in patients with intermediate-risk PE is effective and safe. Methods Echocardiographic and laboratory examinations were performed at baseline (PE diagnosis), 6 days and 6 months. Echocardiographic parameters were classified into categories representing RV size, RV free wall/tricuspid annulus motion, RV pressure overload and right atrial (RA)/central venous pressure. Results RV dysfunction based on any abnormal echocardiographic parameter was present in 84% of patients at baseline. RV dilatation was the most frequently abnormal finding (40.6%), followed by increased RA/central venous pressure (34.6%), RV pressure overload (32.1%), and reduced RV free wall/tricuspid annulus motion (20.9%). As early as day 6, RV size remained normal or improved in 260 patients (64.7%), RV free wall/tricuspid annulus motion in 301 (74.9%), RV pressure overload in 297 (73.9%), and RA/central venous pressure in 254 (63.2%). At day 180, the frequencies slightly increased. The median NT-proBNP level decreased from 1448 pg/ml at baseline to 256.5 on day 6 and 127 on day 180. Conclusion In the majority of patients with acute intermediate-risk PE switched early to a direct oral anticoagulant, echocardiographic parameters of RV function normalised within 6 days and remained normal throughout the first 6 months. Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term. Graphical Abstract

Published
2022

11. Percutaneous edge-to-edge repair for systemic tricuspid valve regurgitation in patients with congenital heart disease: the first descriptive cohort

Author

Guerin, P, primary, Jalal, Z, additional, Cueff, C, additional, Hascoet, S, additional, Bouvaist, H, additional, Levy, F, additional, Hugues, N, additional, Ladouceur, M, additional, Malekzadeh-Milani, S G, additional, Iriart, X, additional, Silini, A, additional, Karam, N, additional, Iserin, L, additional, Le Gloan, L, additional, and Thambo, J B, additional

Published
2022
Full Text
View/download PDF

12. Is brain angio-MRI useful in infective endocarditis management?

Author

Champey, J., Pavese, P., Bouvaist, H., Maillet, M., Kastler, A., Boussat, B., Francois, P., Schwebel, Carole, Bonadona, Agnès, Hamiflar, Rebecca, Vanzetto, Gerald, Dessertaine, Géraldine, Boignard, Aude, Augier, Caroline, Pierre, Isabelle, Brion, Jean-Paul, Wintenberger, Claire, Hincky-Vitrat, Virginie, Forestier, Emmanuel, and and the investigator groups

Published
2016
Full Text
View/download PDF

14. Prognostic significance of severe coronary microvascular dysfunction post-PCI in patients with STEMI: A systematic review and meta-analysis

Author

Canu, M., primary, Khouri, C., additional, Marliere, S., additional, Vautrin, E., additional, Piliero, N., additional, Ormezzano, O., additional, Bertrand, B., additional, Bouvaist, H., additional, Riou, L., additional, Djaileb, L., additional, Charlon, C., additional, Vanzetto, G., additional, Roustit, M., additional, and Barone-Rochette, G., additional

Published
2022
Full Text
View/download PDF

15. BPA and Riociguat for the Management of Inoperable CTEPH: Results of the Extension Study Following the RACE Randomized Controlled Trial (RCT)

Author

Jais, X., primary, Brenot, P., additional, Bouvaist, H., additional, Canuet, M., additional, Chabanne, C., additional, Chaouat, A., additional, Cottin, V., additional, Degroote, P., additional, Favrolt, N., additional, Horeau-Langlard, D., additional, Jevnikar, M., additional, Magro, P., additional, Montani, D., additional, Parent, F., additional, Pison, C., additional, Prévot, G., additional, Renard, S., additional, Savale, L., additional, Sitbon, O., additional, Trésorier, R., additional, Tromeur, C., additional, Piedvache, C., additional, Fadel, E., additional, Humbert, M., additional, and Simonneau, G., additional

Published
2021
Full Text
View/download PDF

18. Impact of use stent with a polyethylene terephthalate micro-net covering on coronary microvascular dysfunction in patients with acute myocardial infarction

Author

Noirclerc, N., primary, Marliere, S., additional, Bakhti, A., additional, Mangin, L., additional, Cassar, E., additional, Belle, L., additional, Bonnet, H., additional, Djebbar, R., additional, Canu, M., additional, Blanc Vannet, S., additional, Vautrin, E., additional, Piliero, N., additional, Ormezzano, O., additional, Bertrand, B., additional, Bouvaist, H., additional, Vanzetto, G., additional, and Barone-Rochette, G., additional

Published
2021
Full Text
View/download PDF

19. Coût hospitalier de l’angioplastie artérielle pulmonaire par ballonnet (AAPB) : étude observationnelle à partir des données du programme de médicalisation des systèmes d’information (PMSI)

Author

Cottin, V., primary, Brenot, P., additional, Bensimon, L., additional, Raguideau, F., additional, Chaize, G., additional, Hakme, A., additional, Levy-Bachelot, L., additional, Vainchtock, A., additional, Dallongeville, J., additional, and Bouvaist, H., additional

Published
2021
Full Text
View/download PDF

20. PCV25 Hospital Costs of Balloon Pulmonary Angioplasty (BPA) Procedure and Management for Chronic Thromboembolic Hypertension Patients: An Observational Study Based on the French National Hospital Discharge Database (PMSI)

Author

Cottin, V., primary, Bensimon, L., additional, Raguideau, F., additional, Chaize, G., additional, Hakmé, A., additional, Levy-Bachelot, L., additional, Vainchtock, A., additional, Dallongeville, J., additional, Bouvaist, H., additional, and Brenot, P., additional

Published
2020
Full Text
View/download PDF

21. HIV Infection and Long‐Term Residual Cardiovascular Risk After Acute Coronary Syndrome

Author

Boccara, Franck, primary, Mary‐Krause, Murielle, additional, Potard, Valérie, additional, Teiger, Emmanuel, additional, Lang, Sylvie, additional, Hammoudi, Nadjib, additional, Chauvet, Marion, additional, Ederhy, Stéphane, additional, Dufour‐Soulat, Laurie, additional, Ancedy, Yann, additional, Nhan, Pascal, additional, Adavane, Saroumadi, additional, Steg, Ph. Gabriel, additional, Funck‐Brentano, Christian, additional, Costagliola, Dominique, additional, Cohen, Ariel, additional, Weber, S., additional, Wahbi, K., additional, Beaufils, P., additional, Henri, P., additional, Sideris, G., additional, Thomas, D., additional, Montalescot, G., additional, Beygui, F., additional, Meuleman, C., additional, Janower, S., additional, Raoux, F., additional, Dufaitre, G., additional, Benyounes, N., additional, Michel, P. L., additional, Petillon, B., additional, Hammoudi, N., additional, Gueret, P., additional, Dubois‐Rande, J. L., additional, Teiger, E., additional, Lim, P., additional, Slama, M., additional, Colin, P., additional, Saudubray, C., additional, Dubourg, O., additional, Milleron, O., additional, Gallet, B., additional, Duclos, F., additional, Godard, S., additional, Fuchs, L., additional, Dormagen, V., additional, Lewy, P., additional, Cattan, S., additional, Nallet, O., additional, Grollier, G., additional, Shayne, J., additional, Wolf, J. E., additional, Cottin, Y., additional, Machecourt, J., additional, Bouvaist, H., additional, Finet, G., additional, De Breyne, B., additional, Trochu, J. N., additional, Baudouy, M., additional, Ferrari, E., additional, Benhamou, M., additional, Allal, J., additional, Coisne, D., additional, Le Breton, H., additional, Bedossa, M., additional, Puel, J., additional, Elbaz, M., additional, Larifla, L., additional, Matheron, S., additional, Landman, R., additional, Fremont, G., additional, Spiridon, G., additional, Blanche, P., additional, Morini, J. P., additional, Sicard, D., additional, Zeller, V., additional, Batisse, D., additional, Clevenbergh, P., additional, Cessot, G., additional, Dohin, E., additional, Valantin, M. A., additional, Khelifa, S., additional, Girard, P. M., additional, Lallemand, F., additional, Lefebvre, B., additional, Laporte, J. P., additional, Meynard, J. L., additional, Bideault, H., additional, Picard, O., additional, Meyohas, M. C., additional, Campa, P., additional, Tredup, J., additional, Fonquernie, L., additional, Raguin, G., additional, Molina, J. M., additional, Furco, A., additional, Gharakanian, S., additional, Vincensini, J. P., additional, Guiard‐Schmid, J. B., additional, Pialoux, G., additional, Cardon, B., additional, Lascaux, A. S., additional, Chaix, F., additional, Lesprit, P., additional, Fior, R., additional, Boue, F., additional, Dupont, C., additional, Bellier, C., additional, Blanc, A., additional, Lambert, T., additional, Touahri, T., additional, Force, G., additional, de Truchis, P., additional, Compagnucci‐Seguenot, M. A., additional, Cahitte, I., additional, Roudière, L., additional, Techer, M. E., additional, Thelpin, P., additional, Troisvallets, D., additional, Lepretre, A., additional, Echard, M., additional, Le Mercier, Y., additional, Houlbert, D., additional, Dargere, S., additional, Bazin, C., additional, Verdon, R., additional, De Goer, B., additional, Duong, M., additional, Chavanet, P., additional, Gozlan, E., additional, Leclercq, P., additional, Brunel‐Dal Mas, F., additional, Durant, J., additional, Heudier, P., additional, Brunet‐François, C., additional, Le Moal, G., additional, Chapplin, J. M., additional, Arvieux, C., additional, Chaumentin, G., additional, Guerin, B., additional, Bonnet, E., additional, Poinsignon, Y., additional, Boulard, F., additional, De Lacroix, I., additional, Goerger‐Sow, M. T., additional, Kirstetter, M., additional, Volstein, M., additional, Laylavoix, F., additional, Copin, X., additional, and Ceppi, C., additional

Published
2020
Full Text
View/download PDF

22. Mid-term outcomes after percutaneous pulmonary valve implantation in complex right ventricular outflow tracts using the “folded” Melody® valve technique

Author

Valdeolmillos, E., primary, Jalal, Z., additional, Georgiev, S., additional, Eicken, A., additional, Hofbeck, M., additional, Sieverding, L., additional, Gewillig, M., additional, Ovaert, C., additional, Bouvaist, H., additional, Boudjemline, Y., additional, and Benoit, J.B., additional

Published
2020
Full Text
View/download PDF

23. Mitral and aortic paravalvular leaks closure: Insights from the prospective international multicenter FFPP cohort study

Author

Hascoët, S., primary, Smolka, G., additional, Champagnac, D., additional, Brochet, E., additional, Bauer, F., additional, Pilliere, R., additional, Lavie-Badie, Y., additional, Nejjari, M., additional, Leurent, G., additional, Spaulding, C., additional, Combes, N., additional, Mangin, L., additional, Hammoudi, N., additional, Dauphin, C., additional, Aminian, A., additional, Ciobotaru, V., additional, Bouvaist, H., additional, Iriart, X., additional, Armero, S., additional, and Gerardin, B., additional

Published
2020
Full Text
View/download PDF

24. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Author

Galie, N, Humbert, M, Vachiery, J, Gibbs, S, Lang, I, Torbicki, A, Simonneau, G, Peacock, A, Vonk Noordegraaf, A, Beghetti, M, Ghofrani, A, Gomez Sanchez, M, Hansmann, G, Klepetko, W, Lancellotti, P, Matucci, M, Mcdonagh, T, Pierard, L, Trindade, P, Zompatori, M, Hoeper, M, Aboyans, V, Vaz Carneiro, A, Achenbach, S, Agewall, S, Allanore, Y, Asteggiano, R, Badano, L, Albert Barbera, J, Bouvaist, H, Bueno, H, Byrne, R, Carerj, S, Castro, G, Erol, C, Falk, V, Funck-Brentano, C, Gorenflo, M, Granton, J, Iung, B, Kiely, D, Kirchhof, P, Kjellstrom, B, Landmesser, U, Lekakis, J, Lionis, C, Lip, G, Orfanos, S, Park, M, Piepoli, M, Ponikowski, P, Revel, M, Rigau, D, Rosenkranz, S, Voller, H, Luis Zamorano, J, Myftiu, S, Bonderman, D, Firdovsi, I, Lazareva, I, De Pauw, M, Sokolovic, S, Velchev, V, Cikes, M, Moutiris, J, Jansa, P, Nielsen-Kudsk, J, Anton, L, Jaaskelainen, P, Bauer, F, Chukhrukidze, A, Opitz, C, Giannakoulas, G, Karlocai, K, Oddsson, O, Gaine, S, Menachemi, D, Emdin, M, Sooronbaev, T, Rudzitis, A, Gumbiene, L, Lebrun, F, Micallef, J, Botnaru, V, Oukerraj, L, Andreassen, A, Kurzyna, M, Leite Baptista, M, Coman, I, Moiseeva, O, Stefanovic, B, Simkova, I, Wikstrom, G, Schwerzmann, M, Srbinovska-Kostovska, E, van Dijk, A, Mahdhaoui, A, Kaymaz, C, Coghlan, G, Sirenko, Y, Galie N., Humbert M., Vachiery J. -L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., Ghofrani A., Gomez Sanchez M. A., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L. A., Trindade P. T., Zompatori M., Hoeper M., Aboyans V., Vaz Carneiro A., Achenbach S., Agewall S., Allanore Y., Asteggiano R., Badano L., Albert Barbera J., Bouvaist H., Bueno H., Byrne R. A., Carerj S., Castro G., Erol C., Falk V., Funck-Brentano C., Gorenflo M., Granton J., Iung B., Kiely D. G., Kirchhof P., Kjellstrom B., Landmesser U., Lekakis J., Lionis C., Lip G. Y. H., Orfanos S. E., Park M. H., Piepoli M. F., Ponikowski P., Revel M. -P., Rigau D., Rosenkranz S., Voller H., Luis Zamorano J., Myftiu S., Bonderman D., Firdovsi I., Lazareva I., De Pauw M., Sokolovic S., Velchev V., Cikes M., Moutiris J. A., Jansa P., Nielsen-Kudsk J. E., Anton L., Jaaskelainen P., Bauer F., Chukhrukidze A., Opitz C., Giannakoulas G., Karlocai K., Oddsson O., Gaine S., Menachemi D., Emdin M., Sooronbaev T., Rudzitis A., Gumbiene L., Lebrun F., Micallef J., Botnaru V., Oukerraj L., Andreassen A. K., Kurzyna M., Leite Baptista M. J. R., Coman I. M., Moiseeva O., Stefanovic B. S., Simkova I., Wikstrom G., Schwerzmann M., Srbinovska-Kostovska E., van Dijk A. P. J., Mahdhaoui A., Kaymaz C., Coghlan G., Sirenko Y., Galie, N, Humbert, M, Vachiery, J, Gibbs, S, Lang, I, Torbicki, A, Simonneau, G, Peacock, A, Vonk Noordegraaf, A, Beghetti, M, Ghofrani, A, Gomez Sanchez, M, Hansmann, G, Klepetko, W, Lancellotti, P, Matucci, M, Mcdonagh, T, Pierard, L, Trindade, P, Zompatori, M, Hoeper, M, Aboyans, V, Vaz Carneiro, A, Achenbach, S, Agewall, S, Allanore, Y, Asteggiano, R, Badano, L, Albert Barbera, J, Bouvaist, H, Bueno, H, Byrne, R, Carerj, S, Castro, G, Erol, C, Falk, V, Funck-Brentano, C, Gorenflo, M, Granton, J, Iung, B, Kiely, D, Kirchhof, P, Kjellstrom, B, Landmesser, U, Lekakis, J, Lionis, C, Lip, G, Orfanos, S, Park, M, Piepoli, M, Ponikowski, P, Revel, M, Rigau, D, Rosenkranz, S, Voller, H, Luis Zamorano, J, Myftiu, S, Bonderman, D, Firdovsi, I, Lazareva, I, De Pauw, M, Sokolovic, S, Velchev, V, Cikes, M, Moutiris, J, Jansa, P, Nielsen-Kudsk, J, Anton, L, Jaaskelainen, P, Bauer, F, Chukhrukidze, A, Opitz, C, Giannakoulas, G, Karlocai, K, Oddsson, O, Gaine, S, Menachemi, D, Emdin, M, Sooronbaev, T, Rudzitis, A, Gumbiene, L, Lebrun, F, Micallef, J, Botnaru, V, Oukerraj, L, Andreassen, A, Kurzyna, M, Leite Baptista, M, Coman, I, Moiseeva, O, Stefanovic, B, Simkova, I, Wikstrom, G, Schwerzmann, M, Srbinovska-Kostovska, E, van Dijk, A, Mahdhaoui, A, Kaymaz, C, Coghlan, G, Sirenko, Y, Galie N., Humbert M., Vachiery J. -L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., Ghofrani A., Gomez Sanchez M. A., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L. A., Trindade P. T., Zompatori M., Hoeper M., Aboyans V., Vaz Carneiro A., Achenbach S., Agewall S., Allanore Y., Asteggiano R., Badano L., Albert Barbera J., Bouvaist H., Bueno H., Byrne R. A., Carerj S., Castro G., Erol C., Falk V., Funck-Brentano C., Gorenflo M., Granton J., Iung B., Kiely D. G., Kirchhof P., Kjellstrom B., Landmesser U., Lekakis J., Lionis C., Lip G. Y. H., Orfanos S. E., Park M. H., Piepoli M. F., Ponikowski P., Revel M. -P., Rigau D., Rosenkranz S., Voller H., Luis Zamorano J., Myftiu S., Bonderman D., Firdovsi I., Lazareva I., De Pauw M., Sokolovic S., Velchev V., Cikes M., Moutiris J. A., Jansa P., Nielsen-Kudsk J. E., Anton L., Jaaskelainen P., Bauer F., Chukhrukidze A., Opitz C., Giannakoulas G., Karlocai K., Oddsson O., Gaine S., Menachemi D., Emdin M., Sooronbaev T., Rudzitis A., Gumbiene L., Lebrun F., Micallef J., Botnaru V., Oukerraj L., Andreassen A. K., Kurzyna M., Leite Baptista M. J. R., Coman I. M., Moiseeva O., Stefanovic B. S., Simkova I., Wikstrom G., Schwerzmann M., Srbinovska-Kostovska E., van Dijk A. P. J., Mahdhaoui A., Kaymaz C., Coghlan G., and Sirenko Y.

Abstract

Document Reviewers: Victor Aboyans (CPG Review Coordinator) (France), Antonio Vaz Carneiro (CPG Review Coordinator) (Portugal), Stephan Achenbach (Germany), Stefan Agewall (Norway), Yannick Allanore (France), Riccardo Asteggiano (Italy), Luigi Paolo Badano (Italy), Joan Albert Barbera (Spain), Helene Bouvaist (France), Hector Bueno (Spain), Robert A. Byrne (Germany), Scipione Carerj (Italy), Graca Castro (Portugal), Cetin Erol (Turkey), Volkmar Falk (Germany), Christian Funck-Brentano (France), Matthias Gorenflo (Germany), John Granton (Canada), Bernard Iung (France), David G. Kiely (UK), Paulus Kirchhof (Germany/UK), Barbro Kjellstrom (Sweden), Ulf Landmesser (Switzerland), John Lekakis (Greece), Christos Lionis (Greece), Gregory Y. H. Lip (UK), Stylianos E. Orfanos (Greece), Myung H. Park (USA), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marie-Pierre Revel (France), David Rigau (ERS methodologist) (Switzerland), Stephan Rosenkranz (Germany), Heinz Voller (Germany), and Jose Luis Zamorano (Spain)

Published
2016

25. ESC/ERS 2015 guidelines for the diagnosis and treatment of pulmonary hypertension

Author

Galie, N, Humbert, M, Vachiery, J, Gibbs, S, Lang, I, Torbicki, A, Simonneau, G, Peacock, A, Noordegraaf, A, Beghetti, M, Ghofrani, A, Sanchez, M, Hansmann, G, Klepetko, W, Lancellotti, P, Matucci, M, Mcdonagh, T, Pierard, L, Trindade, P, Zompatori, M, Hoeper, M, Aboyans, V, Carneiro, A, Achenbach, S, Agewall, S, Allanore, Y, Asteggiano, R, Badano, L, Barbera, J, Bouvaist, H, Bueno, H, Byrne, R, Carerj, S, Castro, G, Erol, C, Falk, V, Funck-Brentano, C, Gorenflo, M, Grantonc, J, Iung, B, Kiely, D, Kirchhof, P, Kjellstrom, B, Landmesser, U, Lekakis, J, Lionis, C, Lip, G, Orfanos, S, Park, M, Piepoli, M, Ponikowski, P, Revel, M, Rigau, D, Rosenkranz, S, Voller, H, Zamorano, J, Galie N., Humbert M., Vachiery J. -L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Noordegraaf A. V., Beghetti M., Ghofrani A., Sanchez M. A. G., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L. A., Trindade P. T., Zompatori M., Hoeper M., Aboyans V., Carneiro A. V., Achenbach S., Agewall S., Allanore Y., Asteggiano R., Badano L., Barbera J. A., Bouvaist H., Bueno H., Byrne R. A., Carerj S., Castro G., Erol C., Falk V., Funck-Brentano C., Gorenflo M., Grantonc J., Iung B., Kiely D. G., Kirchhof P., Kjellstrom B., Landmesser U., Lekakis J., Lionis C., Lip G. Y. H., Orfanos S. E., Park M. H., Piepoli M. F., Ponikowski P., Revel M. -P., Rigau D., Rosenkranz S., Voller H., Zamorano J. L., Galie, N, Humbert, M, Vachiery, J, Gibbs, S, Lang, I, Torbicki, A, Simonneau, G, Peacock, A, Noordegraaf, A, Beghetti, M, Ghofrani, A, Sanchez, M, Hansmann, G, Klepetko, W, Lancellotti, P, Matucci, M, Mcdonagh, T, Pierard, L, Trindade, P, Zompatori, M, Hoeper, M, Aboyans, V, Carneiro, A, Achenbach, S, Agewall, S, Allanore, Y, Asteggiano, R, Badano, L, Barbera, J, Bouvaist, H, Bueno, H, Byrne, R, Carerj, S, Castro, G, Erol, C, Falk, V, Funck-Brentano, C, Gorenflo, M, Grantonc, J, Iung, B, Kiely, D, Kirchhof, P, Kjellstrom, B, Landmesser, U, Lekakis, J, Lionis, C, Lip, G, Orfanos, S, Park, M, Piepoli, M, Ponikowski, P, Revel, M, Rigau, D, Rosenkranz, S, Voller, H, Zamorano, J, Galie N., Humbert M., Vachiery J. -L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Noordegraaf A. V., Beghetti M., Ghofrani A., Sanchez M. A. G., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L. A., Trindade P. T., Zompatori M., Hoeper M., Aboyans V., Carneiro A. V., Achenbach S., Agewall S., Allanore Y., Asteggiano R., Badano L., Barbera J. A., Bouvaist H., Bueno H., Byrne R. A., Carerj S., Castro G., Erol C., Falk V., Funck-Brentano C., Gorenflo M., Grantonc J., Iung B., Kiely D. G., Kirchhof P., Kjellstrom B., Landmesser U., Lekakis J., Lionis C., Lip G. Y. H., Orfanos S. E., Park M. H., Piepoli M. F., Ponikowski P., Revel M. -P., Rigau D., Rosenkranz S., Voller H., and Zamorano J. L.

Published
2016

26. Multimodality imaging guidance for percutaneous paravalvular leak closure: Insights from the multicenter FFPP register

Author

Hascoët, S., primary, Smolka, G., additional, Bagate, F., additional, Hadeed, K., additional, Lavie-Badie, Y., additional, Bouvaist, H., additional, Dauphin, C., additional, Bauer, F., additional, Nejjari, M., additional, Mangin, L., additional, Bonnet, G., additional, Ciobotaru, V., additional, Leurent, G., additional, Hammoudi, N., additional, Aminian, A., additional, Karsenty, C., additional, Armero, S., additional, Champagnac, D., additional, Ternacle, J., additional, and Isorni, M.A., additional

Published
2019
Full Text
View/download PDF

27. ESC/ERS 2015 guidelines for the diagnosis and treatment of pulmonary hypertension

Author

Galie N., Humbert M., Vachiery J. -L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Noordegraaf A. V., Beghetti M., Ghofrani A., Sanchez M. A. G., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L. A., Trindade P. T., Zompatori M., Hoeper M., Aboyans V., Carneiro A. V., Achenbach S., Agewall S., Allanore Y., Asteggiano R., Badano L., Barbera J. A., Bouvaist H., Bueno H., Byrne R. A., Carerj S., Castro G., Erol C., Falk V., Funck-Brentano C., Gorenflo M., Grantonc J., Iung B., Kiely D. G., Kirchhof P., Kjellstrom B., Landmesser U., Lekakis J., Lionis C., Lip G. Y. H., Orfanos S. E., Park M. H., Piepoli M. F., Ponikowski P., Revel M. -P., Rigau D., Rosenkranz S., Voller H., Zamorano J. L., Galie, N, Humbert, M, Vachiery, J, Gibbs, S, Lang, I, Torbicki, A, Simonneau, G, Peacock, A, Noordegraaf, A, Beghetti, M, Ghofrani, A, Sanchez, M, Hansmann, G, Klepetko, W, Lancellotti, P, Matucci, M, Mcdonagh, T, Pierard, L, Trindade, P, Zompatori, M, Hoeper, M, Aboyans, V, Carneiro, A, Achenbach, S, Agewall, S, Allanore, Y, Asteggiano, R, Badano, L, Barbera, J, Bouvaist, H, Bueno, H, Byrne, R, Carerj, S, Castro, G, Erol, C, Falk, V, Funck-Brentano, C, Gorenflo, M, Grantonc, J, Iung, B, Kiely, D, Kirchhof, P, Kjellstrom, B, Landmesser, U, Lekakis, J, Lionis, C, Lip, G, Orfanos, S, Park, M, Piepoli, M, Ponikowski, P, Revel, M, Rigau, D, Rosenkranz, S, Voller, H, and Zamorano, J

Subjects
practice guideline, pulmonary hypertension, human, Review, medical society
Published
2016

28. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

Author

Galie N., Humbert M., Vachiery J. -L., Gibbs S., Lang I., Torbicki A., Simonneau G., Peacock A., Vonk Noordegraaf A., Beghetti M., Ghofrani A., Gomez Sanchez M. A., Hansmann G., Klepetko W., Lancellotti P., Matucci M., McDonagh T., Pierard L. A., Trindade P. T., Zompatori M., Hoeper M., Aboyans V., Vaz Carneiro A., Achenbach S., Agewall S., Allanore Y., Asteggiano R., Badano L., Albert Barbera J., Bouvaist H., Bueno H., Byrne R. A., Carerj S., Castro G., Erol C., Falk V., Funck-Brentano C., Gorenflo M., Granton J., Iung B., Kiely D. G., Kirchhof P., Kjellstrom B., Landmesser U., Lekakis J., Lionis C., Lip G. Y. H., Orfanos S. E., Park M. H., Piepoli M. F., Ponikowski P., Revel M. -P., Rigau D., Rosenkranz S., Voller H., Luis Zamorano J., Myftiu S., Bonderman D., Firdovsi I., Lazareva I., De Pauw M., Sokolovic S., Velchev V., Cikes M., Moutiris J. A., Jansa P., Nielsen-Kudsk J. E., Anton L., Jaaskelainen P., Bauer F., Chukhrukidze A., Opitz C., Giannakoulas G., Karlocai K., Oddsson O., Gaine S., Menachemi D., Emdin M., Sooronbaev T., Rudzitis A., Gumbiene L., Lebrun F., Micallef J., Botnaru V., Oukerraj L., Andreassen A. K., Kurzyna M., Leite Baptista M. J. R., Coman I. M., Moiseeva O., Stefanovic B. S., Simkova I., Wikstrom G., Schwerzmann M., Srbinovska-Kostovska E., van Dijk A. P. J., Mahdhaoui A., Kaymaz C., Coghlan G., Sirenko Y., Galie, N, Humbert, M, Vachiery, J, Gibbs, S, Lang, I, Torbicki, A, Simonneau, G, Peacock, A, Vonk Noordegraaf, A, Beghetti, M, Ghofrani, A, Gomez Sanchez, M, Hansmann, G, Klepetko, W, Lancellotti, P, Matucci, M, Mcdonagh, T, Pierard, L, Trindade, P, Zompatori, M, Hoeper, M, Aboyans, V, Vaz Carneiro, A, Achenbach, S, Agewall, S, Allanore, Y, Asteggiano, R, Badano, L, Albert Barbera, J, Bouvaist, H, Bueno, H, Byrne, R, Carerj, S, Castro, G, Erol, C, Falk, V, Funck-Brentano, C, Gorenflo, M, Granton, J, Iung, B, Kiely, D, Kirchhof, P, Kjellstrom, B, Landmesser, U, Lekakis, J, Lionis, C, Lip, G, Orfanos, S, Park, M, Piepoli, M, Ponikowski, P, Revel, M, Rigau, D, Rosenkranz, S, Voller, H, Luis Zamorano, J, Myftiu, S, Bonderman, D, Firdovsi, I, Lazareva, I, De Pauw, M, Sokolovic, S, Velchev, V, Cikes, M, Moutiris, J, Jansa, P, Nielsen-Kudsk, J, Anton, L, Jaaskelainen, P, Bauer, F, Chukhrukidze, A, Opitz, C, Giannakoulas, G, Karlocai, K, Oddsson, O, Gaine, S, Menachemi, D, Emdin, M, Sooronbaev, T, Rudzitis, A, Gumbiene, L, Lebrun, F, Micallef, J, Botnaru, V, Oukerraj, L, Andreassen, A, Kurzyna, M, Leite Baptista, M, Coman, I, Moiseeva, O, Stefanovic, B, Simkova, I, Wikstrom, G, Schwerzmann, M, Srbinovska-Kostovska, E, van Dijk, A, Mahdhaoui, A, Kaymaz, C, Coghlan, G, and Sirenko, Y

Subjects
Endothelin receptor antagonist, Chronic thromboembolic pulmonary hypertension, Heart failure, Guideline, Prostacyclin analogue, Respiratory failure, Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension, Congenital heart disease, Connective tissue disease, Endothelin receptor antagonists, Guidelines, Heart failure, Left heart disease, Lung disease, Phosphodiesterase type 5 inhibitors, Prostacyclin analogues, Pulmonary arterial hypertension, Pulmonary hypertension, Respiratory failure, Pulmonary hypertension, Phosphodiesterase type 5 inhibitor, Left heart disease, Lung disease, Connective tissue disease, Congenital heart disease
Abstract

Document Reviewers: Victor Aboyans (CPG Review Coordinator) (France), Antonio Vaz Carneiro (CPG Review Coordinator) (Portugal), Stephan Achenbach (Germany), Stefan Agewall (Norway), Yannick Allanore (France), Riccardo Asteggiano (Italy), Luigi Paolo Badano (Italy), Joan Albert Barbera (Spain), Helene Bouvaist (France), Hector Bueno (Spain), Robert A. Byrne (Germany), Scipione Carerj (Italy), Graca Castro (Portugal), Cetin Erol (Turkey), Volkmar Falk (Germany), Christian Funck-Brentano (France), Matthias Gorenflo (Germany), John Granton (Canada), Bernard Iung (France), David G. Kiely (UK), Paulus Kirchhof (Germany/UK), Barbro Kjellstrom (Sweden), Ulf Landmesser (Switzerland), John Lekakis (Greece), Christos Lionis (Greece), Gregory Y. H. Lip (UK), Stylianos E. Orfanos (Greece), Myung H. Park (USA), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Marie-Pierre Revel (France), David Rigau (ERS methodologist) (Switzerland), Stephan Rosenkranz (Germany), Heinz Voller (Germany), and Jose Luis Zamorano (Spain)

Published
2016

29. Incidence and prevention of infective endocarditis and bacteraemia after transcatheter aortic valve implantation in a French university hospital: a retrospective study

Author

Gallouche, M., primary, Barone-Rochette, G., additional, Pavese, P., additional, Bertrand, B., additional, Vanzetto, G., additional, Bouvaist, H., additional, Pierre, I., additional, Schmitt, D., additional, Fauconnier, J., additional, Caspar, Y., additional, Recule, C., additional, Picot-Guéraud, R., additional, Stahl, J.P., additional, Mallaret, M.R., additional, and Landelle, C., additional

Published
2018
Full Text
View/download PDF

30. Airway microbiota signals anabolic and catabolic remodeling in the transplanted lung

Author

Mouraux, Stéphane, primary, Bernasconi, Eric, additional, Pattaroni, Céline, additional, Koutsokera, Angela, additional, Aubert, John-David, additional, Claustre, Johanna, additional, Pison, Christophe, additional, Royer, Pierre-Joseph, additional, Magnan, Antoine, additional, Kessler, Romain, additional, Benden, Christian, additional, Soccal, Paola M., additional, Marsland, Benjamin J., additional, Nicod, Laurent P., additional, Jougon, J., additional, Velly, J.-F., additional, Rozé, H., additional, Blanchard, E., additional, Dromer, C., additional, Antoine, M., additional, Cappello, M., additional, Ruiz, M., additional, Sokolow, Y., additional, Vanden Eynden, F., additional, Van Nooten, G., additional, Barvais, L., additional, Berré, J., additional, Brimioulle, S., additional, De Backer, D., additional, Créteur, J., additional, Engelman, E., additional, Huybrechts, I., additional, Ickx, B., additional, Preiser, T.J.C., additional, Tuna, T., additional, Van Obberghe, L., additional, Vancutsem, N., additional, Vincent, J.-L., additional, De Vuyst, P., additional, Etienne, I., additional, Féry, F., additional, Jacobs, F., additional, Knoop, C., additional, Vachiéry, J.L., additional, Van den Borne, P., additional, Wellemans, I., additional, Amand, G., additional, Collignon, L., additional, Giroux, M., additional, Angelescu, D., additional, Chavanon, O., additional, Hacini, R., additional, Pirvu, A., additional, Porcu, P., additional, Albaladejo, P., additional, Allègre, C., additional, Bataillard, A., additional, Bedague, D., additional, Briot, E., additional, Casez-Brasseur, M., additional, Colas, D., additional, Dessertaine, G., additional, Durand, M., additional, Francony, G., additional, Hebrard, A., additional, Marino, M.R., additional, Oummahan, B., additional, Protar, D., additional, Rehm, D., additional, Robin, S., additional, Rossi-Blancher, M., additional, Augier, C., additional, Bedouch, P., additional, Boignard, A., additional, Bouvaist, H., additional, Briault, A., additional, Camara, B., additional, Claustre, J., additional, Chanoine, S., additional, Dubuc, M., additional, Quétant, S., additional, Maurizi, J., additional, Pavèse, P., additional, Pison, C., additional, Saint-Raymond, C., additional, Wion, N., additional, Chérion, C., additional, Grima, R., additional, Jegaden, O., additional, Maury, J.-M., additional, Tronc, F., additional, Flamens, C., additional, Paulus, S., additional, Mornex, J.-F., additional, Philit, F., additional, Senechal, A., additional, Glérant, J.-C., additional, Turquier, S., additional, Gamondes, D., additional, Chalabresse, L., additional, Thivolet-Bejui, F., additional, Barnel, C., additional, Dubois, C., additional, Tiberghien, A., additional, Le Pimpec-Barthes, F., additional, Bel, A., additional, Mordant, P., additional, Achouh, P., additional, Boussaud, V., additional, Guillemain, R., additional, Méléard, D., additional, Bricourt, M.O., additional, Cholley, B., additional, Pezella, V., additional, Brioude, G., additional, D'Journo, X.B., additional, Doddoli, C., additional, Thomas, P., additional, Trousse, D., additional, Dizier, S., additional, Leone, M., additional, Papazian, L., additional, Bregeon, F., additional, Basire, A., additional, Coltey, B., additional, Dufeu, N., additional, Dutau, H., additional, Garcia, S., additional, Gaubert, J.Y., additional, Gomez, C., additional, Laroumagne, S., additional, Nieves, A., additional, Picard, L.C., additional, Reynaud-Gaubert, M., additional, Secq, V., additional, Mouton, G., additional, Baron, O., additional, Lacoste, P., additional, Perigaud, C., additional, Roussel, J.C., additional, Danner, I., additional, Haloun, A., additional, Magnan, A., additional, Tissot, A., additional, Lepoivre, T., additional, Treilhaud, M., additional, Botturi-Cavaillès, K., additional, Brouard, S., additional, Danger, R., additional, Loy, J., additional, Morisset, M., additional, Pain, M., additional, Pares, S., additional, Reboulleau, D., additional, Royer, P.-J., additional, Fabre, D., additional, Fadel, E., additional, Mercier, O., additional, Mussot, S., additional, Stephan, F., additional, Viard, P., additional, Cerrina, J., additional, Dorfmuller, P., additional, Ghigna, S.M., additional, Hervén, Ph., additional, Le Roy Ladurie, F., additional, Le Pavec, J., additional, Thomas de Montpreville, V., additional, Lamrani, L., additional, Castier, Y., additional, Cerceau, P., additional, Augustin, P., additional, Jean-Baptiste, S., additional, Boudinet, S., additional, Montravers, P., additional, Brugière, O., additional, Dauriat, G., additional, Jébrak, G., additional, Mal, H., additional, Marceau, A., additional, Métivier, A.-C., additional, Thabut, G., additional, Lhuillier, E., additional, Dupin, C., additional, Bunel, V., additional, Falcoz, P., additional, Massard, G., additional, Santelmo, N., additional, Ajob, G., additional, Collange, O., additional, Helms, O., additional, Hentz, J., additional, Roche, A., additional, Bakouboula, B., additional, Degot, T., additional, Dory, A., additional, Hirschi, S., additional, Ohlmann-Caillard, S., additional, Kessler, L., additional, Kessler, R., additional, Schuller, A., additional, Bennedif, K., additional, Vargas, S., additional, Stauder, J., additional, Ali-Azouaou, S., additional, Bonnette, P., additional, Chapelier, A., additional, Puyo, P., additional, Sage, E., additional, Bresson, J., additional, Caille, V., additional, Cerf, C., additional, Devaquet, J., additional, Dumans-Nizard, V., additional, Felten, M.-L., additional, Fischler, M., additional, Si Larbi, A.-G., additional, Leguen, M., additional, Ley, L., additional, Liu, N., additional, Trebbia, G., additional, De Miranda, S., additional, Douvry, B., additional, Gonin, F., additional, Grenet, D., additional, Hamid, A.M., additional, Neveu, H., additional, Parquin, F., additional, Picard, C., additional, Roux, A., additional, Stern, M., additional, Bouillioud, F., additional, Cahen, P., additional, Colombat, M., additional, Dautricourt, C., additional, Delahousse, M., additional, D'Urso, B., additional, Gravisse, J., additional, Guth, A., additional, Hillaire, S., additional, Honderlick, P., additional, Lequintrec, M., additional, Longchampt, E., additional, Mellot, F., additional, Scherrer, A., additional, Temagoult, L., additional, Tricot, L., additional, Vasse, M., additional, Veyrie, C., additional, Zemoura, L., additional, Berjaud, J., additional, Brouchet, L., additional, Dahan, M., additional, Mathe, F.O., additional, Benahoua, H., additional, DaCosta, M., additional, Serres, I., additional, Merlet-Dupuy, V., additional, Grigoli, M., additional, Didier, A., additional, Murris, M., additional, Crognier, L., additional, Fourcade, O., additional, Krueger, T., additional, Ris, H.B., additional, Gonzalez, M., additional, Jolliet, Ph., additional, Marcucci, C., additional, Chollet, M., additional, Gronchi, F., additional, Courbon, C., additional, Berutto, C., additional, Manuel, O., additional, Koutsokera, A., additional, Aubert, J.-D., additional, Nicod, L.P., additional, Mouraux, S., additional, Bernasconi, E., additional, Pattaroni, C., additional, Marsland, B.J., additional, Soccal, P.M., additional, Rochat, T., additional, Lücker, L.M., additional, Hillinger, S., additional, Inci, I., additional, Weder, W., additional, Schuepbach, R., additional, Zalunardo, M., additional, Benden, C., additional, Schuurmans, M.M., additional, Gaspert, A., additional, Holzmann, D., additional, Müller, N., additional, Schmid, C., additional, Vrugt, B., additional, Fritz, A., additional, Maier, D., additional, Deplanche, K., additional, Koubi, D., additional, Ernst, F., additional, Paprotka, T., additional, Schmitt, M., additional, Wahl, B., additional, Boissel, J.-P., additional, Olivera-Botello, G., additional, Trocmé, C., additional, Toussaint, B., additional, Bourgoin-Voillard, S., additional, Sève, M., additional, Benmerad, M., additional, Siroux, V., additional, Slama, R., additional, Auffray, C., additional, Charron, D., additional, Lefaudeux, D., additional, and Pellet, J., additional

Published
2018
Full Text
View/download PDF

33. Outcome of adults with Eisenmenger syndrome treated with pulmonary arterial hypertension-specific drugs in a French multicenter study

Author

Hascoet, S., primary, Fournier, E., additional, Legloan, L., additional, Dauphin, C., additional, Houeijeh, A., additional, Basquin, A., additional, Iriart, X., additional, Richard, A., additional, Barre, E., additional, Bosser, G., additional, Bouvaist, H., additional, Amedro, P., additional, Souletie, N., additional, Radojevic, J., additional, Mauran, P., additional, Moceri, P., additional, Bernard, Y., additional, Bonnet, D., additional, Humbert, M., additional, and Ladouceur, M., additional

Published
2018
Full Text
View/download PDF

36. Blood CD9+B cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation

Author

Brosseau, Carole, Danger, Richard, Durand, Maxim, Durand, Eugénie, Foureau, Aurore, Lacoste, Philippe, Tissot, Adrien, Roux, Antoine, Reynaud‐Gaubert, Martine, Kessler, Romain, Mussot, Sacha, Dromer, Claire, Brugière, Olivier, Mornex, Jean François, Guillemain, Romain, Claustre, Johanna, Magnan, Antoine, Brouard, Sophie, Jougon, J., Velly, J.‐F., Rozé, H., Blanchard, E., Antoine, M., Cappello, M., Ruiz, M., Sokolow, Y., Vanden Eynden, F, Van Nooten, G., Barvais, L., Berré, J., Brimioulle, S., De Backer, D., Créteur, J., Engelman, E, Huybrechts, I., Ickx, B., Preiser, T.J.C., Tuna, T., Van Obberghe, L., Vancutsem, N., Vincent, J.‐L., De Vuyst, P., Etienne, I., Féry, F., Jacobs, F., Knoop, C., Vachiéry, J.L., Van den Borne, P., Wellemans, I., Amand, G., Collignon, L., Giroux, M., Angelescu, D., Chavanon, O., Hacini, R., Martin, C., Pirvu, A., Porcu, P., Albaladejo, P., Allègre, C., Bataillard, A., Bedague, D., Briot, E., Casez‐Brasseur, M., Colas, D., Dessertaine, G., Francony, G., Hebrard, A., Marino, M.R., Protar, D., Rehm, D., Robin, S, Rossi‐Blancher, M., Augier, C., Bedouch, P., Boignard, A., Bouvaist, H., Briault, A., Camara, B., Chanoine, S., Dubuc, M., Quétant, S., Maurizi, J., Pavèse, P., Pison, C., Saint‐Raymond, C., Wion, N., Chérion, C., Grima, R., Jegaden, O., Maury, J.‐M., Tronc, F., Flamens, C., Paulus, S., Philit, F., Senechal, A., Glérant, J.‐C., Turquier, S., Gamondes, D., Chalabresse, L., Thivolet‐Bejui, F., Barnel, C., Dubois, C., Tiberghien, A., Pimpec‐Barthes, F., Bel, A., Mordant, P., Achouh, P., Boussaud, V., Méléard, D., Bricourt, M.O., Cholley, B., Pezella, V., Brioude, G., D'Journo, X.B., Doddoli, C., Thomas, P., Trousse, D., Dizier, S., Leone, M., Papazian, L., Bregeon, F., Coltey, B., Dufeu, N., Dutau, H., Garcia, S., Gaubert, J.Y., Gomez, C., Laroumagne, S., Mouton, G., Nieves, A., Picard, Ch., Rolain, J.M., Sampol, E., Secq, V., Perigaud, C., Roussel, J.C., Senage, T., Mugniot, A., Danner, I., Haloun, A., Abbes, S., Bry, C., Blanc, F.X., Lepoivre, T., Botturi‐Cavaillès, K., Loy, J., Bernard, M., Godard, E., Royer, P.‐J., Henrio, K., Dartevelle, Ph., Fabre, D., Fadel, E., Mercier, O., Stephan, F., Viard, P., Cerrina, J., Dorfmuller, P., Feuillet, S., Ghigna, M., Hervén, Ph., Le Roy Ladurie, F., Le Pavec, J., Thomas de Montpreville, V., Lamrani, L., Castier, Y., Mordant, P., Cerceau, P., Augustin, P., Jean‐Baptiste, S., Boudinet, S., Montravers, P., Dauriat, G., Jébrak, G., Mal, H., Marceau, A., Métivier, A.‐C., Thabut, G., Lhuillier, E., Dupin, C., Bunel, V., Falcoz, P., Massard, G., Santelmo, N., Ajob, G., Collange, O., Helms, O., Hentz, J., Roche, A., Bakouboula, B., Degot, T., Dory, A., Hirschi, S., Ohlmann‐Caillard, S., Kessler, L., Schuller, A., Bennedif, K., Vargas, S., Bonnette, P., Chapelier, A., Puyo, P., Sage, E., Bresson, J., Caille, V., Cerf, C., Devaquet, J., Dumans‐Nizard, V., Felten, M.L., Fischler, M., Si Larbi, A.G., Leguen, M., Ley, L., Liu, N., Trebbia, G., De Miranda, S., Douvry, B., Gonin, F., Grenet, D., Hamid, A.M., Neveu, H., Parquin, F., Picard, C., Stern, M., Bouillioud, F., Cahen, P., Colombat, M., Dautricourt, C., Delahousse, M., D'Urso, B., Gravisse, J., Guth, A., Hillaire, S., Honderlick, P., Lequintrec, M., Longchampt, E., Mellot, F., Scherrer, A., Temagoult, L., Tricot, L., Vasse, M., Veyrie, C., Zemoura, L., Dahan, M., Murris, M., Benahoua, H., Berjaud, J., Le Borgne Krams, A., Crognier, L., Brouchet, L., Mathe, O., Didier, A., Krueger, T., Ris, H.B., Gonzalez, M., Aubert, J.‐D., Nicod, L.P., Marsland, B.J., Berutto, T.C., Rochat, T., Soccal, P., Jolliet, Ph., Koutsokera, A., Marcucci, C., Manuel, O., Bernasconi, E., Chollet, M., Gronchi, F., Courbon, C., Hillinger, S., Inci, I., Kestenholz, P., Weder, W., Schuepbach, R., Zalunardo, M., Benden, C., Buergi, U., Huber, L.C., Isenring, B., Schuurmans, M.M., Gaspert, A., Holzmann, D., Müller, N., Schmid, C., Vrugt, B., Rechsteiner, T., Fritz, A., Maier, D., Deplanche, K., Koubi, D., Ernst, F., Paprotka, T., Schmitt, M., Wahl, B., Boissel, J.‐P., Olivera‐Botello, G., Trocmé, C., Toussaint, B., Bourgoin‐Voillard, S., Séve, M., Benmerad, M., Siroux, V., Slama, R., Auffray, C., Charron, D., Lefaudeux, D., and Pellet, J.

Abstract

Bronchiolitis obliterans syndrome is the main limitation for long‐term survival after lung transplantation. Some specific B cell populations are associated with long‐term graft acceptance. We aimed to monitor the B cell profile during early development of bronchiolitis obliterans syndrome after lung transplantation. The B cell longitudinal profile was analyzed in peripheral blood mononuclear cells from patients with bronchiolitis obliterans syndrome and patients who remained stable over 3 years of follow‐up. CD24hiCD38hitransitional B cells were increased in stable patients only, and reached a peak 24 months after transplantation, whereas they remained unchanged in patients who developed a bronchiolitis obliterans syndrome. These CD24hiCD38hitransitional B cells specifically secrete IL‐10 and express CD9. Thus, patients with a total CD9+B cell frequency below 6.6% displayed significantly higher incidence of bronchiolitis obliterans syndrome (AUC = 0.836, PPV = 0.75, NPV = 1). These data are the first to associate IL‐10‐secreting CD24hiCD38hitransitional B cells expressing CD9 with better allograft outcome in lung transplant recipients. CD9‐expressing B cells appear as a contributor to a favorable environment essential for the maintenance of long‐term stable graft function and as a new predictive biomarker of bronchiolitis obliterans syndrome–free survival. In lung transplant patients with bronchiolitis obliterans syndrome and patients who remained stable over 3 years of follow‐up, IL‐10–secreting CD24hiCD38hi transitional B cells expressing CD9 are associated with better allograft outcome, suggesting CD9‐expressing B cells as a new predictive biomarker of bronchiolitis obliterans syndrome–free survival.

Published
2019
Full Text
View/download PDF

39. Diuretic versus placebo in normotensive acute pulmonary embolism with right ventricular enlargement and injury: a double-blind randomised placebo controlled study. Protocol of the DiPER study

Author

Gallet, R., primary, Meyer, G., additional, Ternacle, J., additional, Biendel, C., additional, Brunet, A., additional, Meneveau, N., additional, Rosario, R., additional, Couturaud, F., additional, Sebbane, M., additional, Lamblin, N., additional, Bouvaist, H., additional, Coste, P., additional, Maitre, B., additional, Bastuji-Garin, S., additional, Dubois-Rande, J.-L., additional, and Lim, P., additional

Published
2015
Full Text
View/download PDF

40. T Cells Promote Bronchial Epithelial Cell Secretion of Matrix Metalloproteinase‐9 via a C‐C Chemokine Receptor Type 2 Pathway: Implications for Chronic Lung Allograft Dysfunction

Author

Pain, M., Royer, P.‐J., Loy, J., Girardeau, A., Tissot, A., Lacoste, P., Roux, A., Reynaud‐Gaubert, M., Kessler, R., Mussot, S., Dromer, C., Brugière, O., Mornex, J.‐F., Guillemain, R., Dahan, M., Knoop, C., Botturi, K., Pison, C., Danger, R., Brouard, S., Magnan, A., Jougon, J., Velly, J.‐F., Rozé, H., Blanchard, E., Antoine, M., Cappello, M., Souilamas, R., Ruiz, M., Sokolow, Y., Vanden Eynden, F., Van Nooten, G., Barvais, L., Berré, J., Brimioulle, S., De Backer, D., Créteur, J., Engelman, E., Huybrechts, I., Ickx, B., Preiser, T.J.C., Tuna, T., Van Obberghe, L., Vancutsem, N., Vincent, J.‐L., De Vuyst, P., Etienne, I., Féry, F., Jacobs, F., Vachiéry, J.L., Van den Borne, P., Wellemans, I., Amand, G., Collignon, L., Giroux, M., Arnaud‐Crozat, E., Bach, V., Brichon, P.‐Y., Chaffanjon, P., Chavanon, O., de Lambert, A., Fleury, J.P., Guigard, S., Hireche, K., Pirvu, A., Porcu, P., Hacini, R., Albaladejo, P., Allègre, C., Bataillard, A., Bedague, D., Briot, E., Casez‐Brasseur, M., Colas, D., Dessertaine, G., Durand, M., Francony, G., Hebrard, A., Marino, M.R., Oummahan, B., Protar, D., Rehm, D., Robin, S., Rossi‐Blancher, M., Bedouch, P., Boignard, A., Bouvaist, H., Briault, A., Camara, B., Chanoine, S., Dubuc, M., Lantuéjoul, S., Quétant, S., Maurizi, J., Pavèse, P., Saint‐Raymond, C., Wion, N., Chérion, C., Grima, R., Jegaden, O., Maury, J.‐M., Tronc, F., Flamens, C., Paulus, S., Philit, F., Senechal, A., Glérant, J.‐C., Turquier, S., Gamondes, D., Chalabresse, L., Thivolet‐Bejui, F., Barnel, C., Dubois, C., Tiberghien, A., Le Pimpec‐Barthes, F., Bel, A., Mordant, P., Achouh, P., Boussaud, V., Méléard, D., Bricourt, M.O., Cholley, B., Pezella, V., Adda, M., Badier, M., Bregeon, F., Coltey, B., D'Journo, X.B., Dizier, S., Doddoli, C., Dufeu, N., Dutau, H., Forel, J.M., Gaubert, J.Y., Gomez, C., Leone, M., Nieves, A., Orsini, B., Papazian, L., Picard, C., Roch, A., Rolain, J.M., Sampol, E., Secq, V., Thomas, P., Trousse, D., Yahyaoui, M., Baron, O., Perigaud, C., Roussel, J.C., Danner, I., Haloun, A., Lepoivre, T., Treilhaud, M., Botturi‐Cavaillès, K., Morisset, M., Pares, S., Reboulleau, D., Dartevelle, P., Fabre, D., Fadel, E., Mercier, O., Stephan, F., Viard, P., Cerrina, J., Dorfmuller, P., Feuillet, S., Ghigna, M., Hervén, P., Le Roy Ladurie, F., Le Pavec, J., Thomas de Montpreville, V., Lamrani, L., Castier, Y., Cerceau, P., Francis, F., Lesèche, G., Allou, N., Augustin, P., Boudinet, S., Desmard, M., Dufour, G., Montravers, P., Dauriat, G., Jébrak, G., Mal, H., Marceau, A., Métivier, A.‐C., Thabut, G., Ait Ilalne, B., Falcoz, P., Massard, G., Santelmo, N., Ajob, G., Collange, O., Helms, O., Hentz, J., Roche, A., Bakouboula, B., Degot, T., Dory, A., Hirschi, S., Ohlmann‐Caillard, S., Kessler, L., Schuller, A., Bennedif, K., Vargas, S., Bonnette, P., Chapelier, A., Puyo, P., Sage, E., Bresson, J., Caille, V., Cerf, C., Devaquet, J., Dumans‐Nizard, V., Felten, M.L., Fischler, M., Si Larbi, A.G., Leguen, M., Ley, L., Liu, N., Trebbia, G., De Miranda, S., Douvry, B., Gonin, F., Grenet, D., Hamid, A.M., Neveu, H., Parquin, F., Picard, C., Stern, M., Bouillioud, F., Cahen, P., Colombat, M., Dautricourt, C., Delahousse, M., D'Urso, B., Gravisse, J., Guth, A., Hillaire, S., Honderlick, P., Lequintrec, M., Longchampt, E., Mellot, F., Scherrer, A., Temagoult, L., Tricot, L., Vasse, M., Veyrie, C., Zemoura, L., Berjaud, J., Brouchet, L., Le Balle, F, Mathe, O., Benahoua, H., Didier, A., Goin, A.L., Murris, M., Crognier, L., and Fourcade, O.

Abstract

Chronic lung allograft dysfunction (CLAD) is the major limitation of long‐term survival after lung transplantation. CLADmanifests as bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndrome (RAS). Alloimmune reactions and epithelial‐to‐mesenchymal transition have been suggested in BOS. However, little is known regarding the role of allogenicity in epithelial cell differentiation. Primary human bronchial epithelial cells (BECs) were treated with activated T cells in the presence or absence of transforming growth factor (TGF)‐β. The expression of epithelial and mesenchymal markers was investigated. The secretion of inflammatory cytokines and matrix metalloproteinase (MMP)‐9 was measured in culture supernatants and in plasma from lung transplant recipients (LTRs): 49 stable, 29 with BOS,and 16 with RAS. We demonstrated that C‐C motif chemokine 2 secreted by T cells supports TGF‐β–induced MMP‐9 production by BECsafter binding to C‐C chemokine receptor type 2. Longitudinal investigation in LTRsrevealed a rise in plasma MMP‐9 before CLADonset. Multivariate analysis showed that plasma MMP‐9 was independently associated with BOS(odds ratio [OR] =6.19, p = 0.002) or RAS(OR= 3.9, p = 0.024) and predicted the occurrence of CLAD12 months before the functional diagnosis. Thus, immune cells support airway remodeling through the production of MMP‐9. Plasma MMP‐9 is a potential predictive biomarker of CLAD. The authors investigate the production of matrix metalloproteinase‐9 by primary bronchial epithelial cells after interaction with activated T cells and show that plasma matrix metalloproteinase‐9 can serve as a predictor of chronic lung allograft dysfunction 12 months before clinical diagnosis.

Published
2017
Full Text
View/download PDF

42. Incomplete echocardiographic recovery at 6months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial

Author

Jan Beyer-Westendorf, Cecilia Becattini, Stefano Barco, Nicolas Meneveau, Bożena Sobkowicz, Emile Ferrari, Guy Meyer, Stavros Konstantinides, Laurent Bertoletti, Thierry Danays, Maciej Kostrubiec, Matija Kozak, Sebastian Schellong, Nazzareno Galiè, Frederikus A. Klok, Francis Couturaud, Olivier Sanchez, Aldo Salvi, Piotr Pruszczyk, Christian Kupatt, Mareike Lankeit, Hélène Bouvaist, Klaus Empen, David Jiménez, Matteo Rugolotto, Massimiliano Palazzini, Mariaconcetta Russo, Daniel Duerschmied, Eric Vicaut, Irene M. Lang, Claudia Dellas, Barco S., Russo M., Vicaut E., Becattini C., Bertoletti L., Beyer-Westendorf J., Bouvaist H., Couturaud F., Danays T., Dellas C., Duerschmied D., Empen K., Ferrari E., Galie N., Jimenez D., Klok F.A., Kostrubiec M., Kozak M., Kupatt C., Lang I.M., Lankeit M., Meneveau N., Palazzini M., Pruszczyk P., Rugolotto M., Salvi A., Sanchez O., Schellong S., Sobkowicz B., Meyer G., and Konstantinides S.V.

Subjects
Male, Time Factors, medicine.medical_treatment, Chronic thromboembolic pulmonary hypertension, Post-PE impairment, Pulmonary embolism, Right ventricular dysfunction, Risk stratification, Acute Disease, Disease Progression, Echocardiography, Female, Fibrinolytic Agents, Follow-Up Studies, Heart Ventricles, Humans, Middle Aged, Pulmonary Embolism, Retrospective Studies, Risk Factors, Tenecteplase, Thrombolytic Therapy, Treatment Outcome, Ventricular Function, Right, Recovery of Function, 030204 cardiovascular system & hematology, New york heart association, 0302 clinical medicine, Ventricular Function, 030212 general & internal medicine, General Medicine, Thrombolysis, 3. Good health, ddc, Right, Cardiology, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, 03 medical and health sciences, Internal medicine, Post-hoc analysis, medicine, Original Paper, business.industry, medicine.disease, Pulmonary hypertension, Heart failure, business, Intermediate risk
Abstract

INTRODUCTION: Symptoms and functional limitation are frequently reported by survivors of acute pulmonary embolism (PE). However, current guidelines provide no specific recommendations on which patients should be followed after acute PE, when follow-up should be performed, and which tests it should include. Definition and classification of late PE sequelae are evolving, and their predictors remain to be determined. METHODS: In a post hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial, we focused on 219 survivors of acute intermediate-risk PE with clinical and echocardiographic follow-up 6 months after randomisation as well as over the long term (median, 3 years after acute PE). The primary outcome was a composite of (1) confirmed chronic thromboembolic pulmonary hypertension (CTEPH) or (2) 'post-PE impairment' (PPEI), defined by echocardiographic findings indicating an intermediate or high probability of pulmonary hypertension along with New York Heart Association functional class II-IV. RESULTS: Confirmed CTEPH or PPEI occurred in 29 (13.2%) patients, (6 with CTEPH and 23 with PPEI). A history of chronic heart failure at baseline and incomplete or absent recovery of echocardiographic parameters at 6 months predicted CTEPH or PPEI at long-term follow-up. CONCLUSIONS: CTEPH or PPEI occurs in almost one out of seven patients after acute intermediate-risk PE. Six-month echocardiographic follow-up may be useful for timely detection of late sequelae. peerReviewed

Published
2019

43. Post-capillary pulmonary hypertension in heart failure: impact of current definition in the PH-HF multicentre study.

Author

Fauvel C, Damy T, Berthelot E, Bauer F, Eicher JC, de Groote P, Trochu JN, Picard F, Renard S, Bouvaist H, Logeart D, Roubille F, Sitbon O, and Lamblin N

Subjects
Humans, Male, Female, Middle Aged, Aged, Prognosis, Prospective Studies, Cardiac Catheterization methods, Prevalence, Heart Failure complications, Heart Failure physiopathology, Heart Failure epidemiology, Hypertension, Pulmonary physiopathology, Hypertension, Pulmonary diagnosis, Vascular Resistance physiology
Abstract

Background and Aims: Based on retrospective studies, the 2022 European guidelines changed the definition of post-capillary pulmonary hypertension (pcPH) in heart failure (HF) by lowering the level of mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR). However, the impact of this definition and its prognostic value has never been evaluated prospectively., Methods: Stable left HF patients with the need for right heart catheterization were enrolled from 2010 to 2018 and prospectively followed up in this multicentre study. The impact of the successive pcPH definitions on pcPH prevalence and subgroup [i.e. isolated (IpcPH) vs. combined pcPH (CpcPH)] was evaluated. Multivariable Cox regression analysis was used to assess the prognostic value of mPAP and PVR on all-cause death or hospitalization for HF (primary outcome)., Results: Included were 662 HF patients were (median age 63 years, 60% male). Lowering mPAP from 25 to 20 mmHg resulted in +10% increase in pcPH prevalence, whereas lowering PVR from 3 to 2 resulted in +60% increase in CpcPH prevalence (with significant net reclassification improvement for the primary outcome). In multivariable analysis, both mPAP and PVR remained associated with the primary outcome [hazard ratio (HR) 1.02, 95% confidence interval (CI) 1.00-1.03, P = .01; HR 1.07, 95% CI 1.00-1.14, P = .03]. The best PVR threshold associated with the primary outcome was around 2.2 WU. Using the 2022 definition, pcPH patients had worse survival compared with HF patients without pcPH (log-rank, P = .02) as well as CpcPH compared with IpcPH (log-rank, P = .003)., Conclusions: This study is the first emphasizing the impact of the new pcPH definition on CpcPH prevalence and validating the prognostic value of mPAP > 20 mmHg and PVR > 2 WU among HF patients., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

44. Development and validation of a code-based algorithm using in-hospital medical records to identify patients with pulmonary arterial hypertension in a French healthcare database.

Author

Jambon-Barbara C, Hlavaty A, Bernardeau C, Bouvaist H, Chaumais MC, Humbert M, Montani D, Cracowski JL, and Khouri C

Abstract

Introduction: Pulmonary arterial hypertension (PAH) is a rare and severe disease for which most of the evidence about prognostic factors, evolution and treatment efficacy comes from cohorts, registries and clinical trials. We therefore aimed to develop and validate a new PAH identification algorithm that can be used in the French healthcare database "Système National des Données de Santé (SNDS)"., Methods: We developed and validated the algorithm using the Grenoble Alpes University Hospital medical charts. We first identified PAH patients following a previously validated algorithm, using in-hospital ICD-10 (10th revision of the International Statistical Classification of Diseases) codes, right heart catheterisation procedure and PAH-specific treatment dispensing. Then, we refined the latter with the exclusion of chronic thromboembolic pulmonary hypertension procedures and treatment, the main misclassification factor. Second, we validated this algorithm using a gold standard review of in-hospital medical charts and calculated sensitivity, specificity, positive and negative predictive value (PPV and NPV) and accuracy. Finally, we applied this algorithm in the French healthcare database and described the characteristics of the identified patients., Results: In the Grenoble University Hospital, we identified 252 unique patients meeting all the algorithm's criteria between 1 January 2010 and 30 June 2022, and reviewed all medical records. The sensitivity, specificity, PPV, NPV and accuracy were 91.0%, 74.3%, 67.9%, 93.3% and 80.6%, respectively. Application of this algorithm to the SNDS yielded the identification of 9931 patients with consistent characteristics compared to PAH registries., Conclusion: Overall, we propose a new PAH identification algorithm developed and adapted to the French specificities that can be used in future studies using the French healthcare database., Competing Interests: Conflict of interest: H. Bouvaist reports payment for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Merck, outside the submitted work. Conflict of interest: M. Humbert reports grants or contracts from Acceleron, AOP Orphan, Janssen, Merck and Shou Ti, outside the submitted work; consulting fees from 35 Pharma, Aerovate, AOP Orphan, Bayer, Chiesi, Ferrer, Janssen, Keros, Merck, MorphogenIX, Shou Ti and United Therapeutics, outside the submitted work; payment for lectures, presentations, speakers’ bureaus, manuscript writing or educational events from Janssen and Merck, outside the submitted work; and participation on a data safety monitoring or advisory board for Acceleron, Altavant, Janssen, Merck and United Therapeutics, outside the submitted work. Conflict of interest: D. Montani reports grants or contracts from Acceleron, Janssen and Merck MSD, outside the submitted work; consulting fees from Acceleron, Merck MSD, Janssen and Ferrer, outside the submitted work; payment or honoraria for speakers' bureaus from Bayer, Janssen, Boerhinger, Chiesi, GSK, Ferrer and Merck MSD, outside the submitted work. Conflict of interest: The remaining authors have nothing to disclose., (Copyright ©The authors 2024.)

Published
2024
Full Text
View/download PDF

45. Early hybrid cardiac rehabilitation in congenital heart disease: the QUALIREHAB trial.

Author

Amedro P, Gavotto A, Huguet H, Souilla L, Huby AC, Matecki S, Cadene A, De La Villeon G, Vincenti M, Werner O, Bredy C, Lavastre K, Abassi H, Cohen S, Hascoet S, Dauphin C, Chalard A, Dulac Y, Souletie N, Bouvaist H, Douchin S, Lachaud M, Ovaert C, Soulatges C, Combes N, Thambo JB, Iriart X, Bajolle F, Bonnet D, Ansquer H, Delpey JG, Cohen L, Picot MC, and Guillaumont S

Subjects
Adolescent, Female, Humans, Male, Young Adult, Exercise, Exercise Therapy, Quality of Life, Cardiac Rehabilitation methods, Heart Defects, Congenital
Abstract

Background and Aims: Cardiopulmonary fitness in congenital heart disease (CHD) decreases faster than in the general population resulting in impaired health-related quality of life (HRQoL). As the standard of care seems insufficient to encourage and maintain fitness, an early hybrid cardiac rehabilitation programme could improve HRQoL in CHD., Methods: The QUALIREHAB multicentre, randomized, controlled trial evaluated and implemented a 12-week centre- and home-based hybrid cardiac rehabilitation programme, including multidisciplinary care and physical activity sessions. Adolescent and young adult CHD patients with impaired cardiopulmonary fitness were randomly assigned to either the intervention (i.e. cardiac rehabilitation) or the standard of care. The primary outcome was the change in HRQoL from baseline to 12-month follow-up in an intention-to-treat analysis. The secondary outcomes were the change in cardiovascular parameters, cardiopulmonary fitness, and mental health., Results: The expected number of 142 patients was enroled in the study (mean age 17.4 ± 3.4 years, 52% female). Patients assigned to the intervention had a significant positive change in HRQoL total score [mean difference 3.8; 95% confidence interval (CI) 0.2; 7.3; P = .038; effect size 0.34], body mass index [mean difference -0.7 kg/m2 (95% CI -1.3; -0.1); P = .022; effect size 0.41], level of physical activity [mean difference 2.5 (95% CI 0.1; 5); P = .044; effect size 0.39], and disease knowledge [mean difference 2.7 (95% CI 0.8; 4.6); P = .007; effect size 0.51]. The per-protocol analysis confirmed these results with a higher magnitude of differences. Acceptability, safety, and short-time effect of the intervention were good to excellent., Conclusions: This early hybrid cardiac rehabilitation programme improved HRQoL, body mass index, physical activity, and disease knowledge, in youth with CHD, opening up the possibility for the QUALIREHAB programme to be rolled out to the adult population of CHD and non-congenital cardiac disease., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

46. The RISE Study: Retrospective Registry for the International Safety and Efficacy Results of Patent Foramen Ovale Closure with Figulla Flex Il PFO and UNI Occluders.

Author

Pioch N, Trabattoni D, Bouvaist H, Vautrin E, Teruzzi G, Dollinger C, Rioufol G, Godart F, and Fraisse A

Abstract

Background: Transcatheter closure of a patent foramen ovale (PFO) is performed in cryptogenic stroke and other conditions. Information is lacking for some devices. Methods: We aimed to evaluate the Figulla Flex II PFO Occluder (FFP) and Figulla Flex UNI Occluder (FFU) through a retrospective multi-center registry. Results : 527 patients were included. Mean age was 48.9 (±13.8) years. The procedure was under transthoracic, transesophageal or intracardiac echocardiography in 185 (35.1%), 193 (36.6%) and 149 (28.3%) cases, respectively, and under general anesthesia in 191 patients (36.2%). The FFP and FFU were used in 408 (77.4%) and 119 (22.6%) cases, respectively. The success rate was 99.1%. Median follow-up was 1.1 (0.5-2.5) years. A new atrial fibrillation/flutter within six months occurred in 14 (2.7%) cases, with no difference between devices. One device embolization in the pulmonary artery was identified two years post-procedure. Residual shunts occurred in 18 (6.9%) cases at 1 year, with TIA in three (16.6%) patients. Out of 437 patients with stroke/TIA, 260 (59%) were followed more than one year after closure. Median follow-up was 2.1 (1.17-3.1) years, with four recurrent strokes/TIA. Conclusions: The FFP and FFU devices are safe and effective for PFO closure, with very few atrial fibrillation/flutter and neurologic events, except in cases with a residual shunt., Competing Interests: Alain Fraisse and Francois Godart are both consultants and proctors for Occlutech Inc and Abbott Inc. Other authors have no conflicts of interest.

Published
2024
Full Text
View/download PDF

47. Upfront triple therapy with parenteral prostanoid as a bridge to balloon pulmonary angioplasty in severe chronic thromboembolic pulmonary hypertension.

Author

Piliero N, Salvat M, Finas M, Curioz F, Traclet J, Ahmad K, Bertoletti L, Vautrin E, Bouvaist H, and Degano B

Abstract

In patients with very severe CTEPH eligible for BPA, it is possible to achieve major haemodynamic improvement with upfront triple PH therapy including epoprostenol and then to perform angioplasties https://bit.ly/3vZZvib., Competing Interests: Conflict of interest: The authors have nothing to disclose., (Copyright ©The authors 2024.)

Published
2024
Full Text
View/download PDF

48. Outcomes of transcatheter pulmonary SAPIEN 3 valve implantation: an international registry.

Author

Hascoët S, Bentham JR, Giugno L, Betrián-Blasco P, Kempny A, Houeijeh A, Baho H, Sharma SR, Jones MI, Biernacka EK, Combes N, Georgiev S, Bouvaist H, Martins JD, Kantzis M, Turner M, Schubert S, Jalal Z, Butera G, Malekzadeh-Milani S, Valdeolmillos E, Karsenty C, Ödemiş E, Aldebert P, Haas NA, Khatib I, Wåhlander H, Gaio G, Mendoza A, Arif S, Castaldi B, Dohlen G, Carere RG, Del Cerro-Marin MJ, Kitzmüller E, Hermuzi A, Carminati M, Guérin P, Tengler A, and Fraisse A

Subjects
Adult, Humans, Cardiac Catheterization adverse effects, Prosthesis Design, Registries, Retrospective Studies, Treatment Outcome, Endocarditis epidemiology, Endocarditis, Bacterial complications, Heart Defects, Congenital complications, Heart Valve Prosthesis adverse effects, Heart Valve Prosthesis Implantation adverse effects, Pulmonary Valve surgery, Pulmonary Valve Insufficiency epidemiology, Pulmonary Valve Insufficiency surgery, Thrombosis etiology
Abstract

Background and Aims: Transcatheter pulmonary valve implantation (TPVI) is indicated to treat right-ventricular outflow tract (RVOT) dysfunction related to congenital heart disease (CHD). Outcomes of TPVI with the SAPIEN 3 valve that are insufficiently documented were investigated in the EUROPULMS3 registry of SAPIEN 3-TPVI., Methods: Patient-related, procedural, and follow-up outcome data were retrospectively assessed in this observational cohort from 35 centres in 15 countries., Results: Data for 840 consecutive patients treated in 2014-2021 at a median age of 29.2 (19.0-41.6) years were obtained. The most common diagnosis was conotruncal defect (70.5%), with a native or patched RVOT in 50.7% of all patients. Valve sizes were 20, 23, 26, and 29 mm in 0.4%, 25.5%, 32.1%, and 42.0% of patients, respectively. Valve implantation was successful in 98.5% [95% confidence interval (CI), 97.4%-99.2%] of patients. Median follow-up was 20.3 (7.1-38.4) months. Eight patients experienced infective endocarditis; 11 required pulmonary valve replacement, with a lower incidence for larger valves (P = .009), and four experienced pulmonary valve thrombosis, including one who died and three who recovered with anticoagulation. Cumulative incidences (95%CI) 1, 3, and 6 years after TPVI were as follows: infective endocarditis, 0.5% (0.0%-1.0%), 0.9% (0.2%-1.6%), and 3.8% (0.0%-8.4%); pulmonary valve replacement, 0.4% (0.0%-0.8%), 1.3% (0.2%-2.4%), and 8.0% (1.2%-14.8%); and pulmonary valve thrombosis, 0.4% (0.0%-0.9%), 0.7% (0.0%-1.3%), and 0.7% (0.0%-1.3%), respectively., Conclusions: Outcomes of SAPIEN 3 TPVI were favourable in patients with CHD, half of whom had native or patched RVOTs., (© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2024
Full Text
View/download PDF

49. Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicentre Pulmonary Embolism International Trial (PEITHO)-2.

Author

Mavromanoli AC, Barco S, Ageno W, Bouvaist H, Brodmann M, Cuccia C, Couturaud F, Dellas C, Dimopoulos K, Duerschmied D, Empen K, Faggiano P, Ferrari E, Galiè N, Galvani M, Ghuysen A, Giannakoulas G, Huisman MV, Jiménez D, Kozak M, Lang IM, Meneveau N, Münzel T, Palazzini M, Petris AO, Piovaccari G, Salvi A, Schellong S, Schmidt KH, Verschuren F, Schmidtmann I, Toenges G, Klok FA, and Konstantinides SV

Subjects
Humans, Acute Disease, Echocardiography, Prognosis, Prospective Studies, Ventricular Function, Right, Pulmonary Embolism diagnosis, Pulmonary Embolism drug therapy, Ventricular Dysfunction, Right diagnosis, Ventricular Dysfunction, Right drug therapy
Abstract

Background: Right ventricular (RV) function plays a critical role in the pathophysiology and acute prognosis of pulmonary embolism (PE). We analyzed the temporal changes of RV function in the cohort of a prospective multicentre study investigating if an early switch to oral anticoagulation in patients with intermediate-risk PE is effective and safe., Methods: Echocardiographic and laboratory examinations were performed at baseline (PE diagnosis), 6 days and 6 months. Echocardiographic parameters were classified into categories representing RV size, RV free wall/tricuspid annulus motion, RV pressure overload and right atrial (RA)/central venous pressure., Results: RV dysfunction based on any abnormal echocardiographic parameter was present in 84% of patients at baseline. RV dilatation was the most frequently abnormal finding (40.6%), followed by increased RA/central venous pressure (34.6%), RV pressure overload (32.1%), and reduced RV free wall/tricuspid annulus motion (20.9%). As early as day 6, RV size remained normal or improved in 260 patients (64.7%), RV free wall/tricuspid annulus motion in 301 (74.9%), RV pressure overload in 297 (73.9%), and RA/central venous pressure in 254 (63.2%). At day 180, the frequencies slightly increased. The median NT-proBNP level decreased from 1448 pg/ml at baseline to 256.5 on day 6 and 127 on day 180., Conclusion: In the majority of patients with acute intermediate-risk PE switched early to a direct oral anticoagulant, echocardiographic parameters of RV function normalised within 6 days and remained normal throughout the first 6 months. Almost one in four patients, however, continued to have evidence of RV dysfunction over the long term., (© 2022. The Author(s).)

Published
2023
Full Text
View/download PDF

50. Routine Rehabilitation as a Treatment Component for Patients With Pulmonary Arterial or Chronic Thromboembolic Pulmonary Hypertensions.

Author

Barret T, Degano B, Bouvaist H, Pison C, Noirclerc M, Vanzetto G, and Rocca C

Subjects
Humans, Female, Adult, Middle Aged, Aged, Male, Walk Test, Outpatients, Exercise, Chronic Disease, Hypertension, Pulmonary etiology, Pulmonary Arterial Hypertension
Abstract

Purpose: Patients with pulmonary hypertension (PH) have long been advised to avoid exercise in fear of deterioration in right-sided heart function. Since the 2009 European Society of Cardiology guidelines, rehabilitation in expert centers is considered to have a specific role in care of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). We report routine rehabilitation effects in patients with PH as a component of real-life multimodal treatment., Methods: Patients with PAH or CTEPH were recommended for either in- or outpatient rehabilitation in addition to their usual care, unless there were practical problems or the patient declined. Assessment was conducted according to New York Heart Association classes, adverse events, 6 min-walk test, hemodynamics, and risk stratification after rehabilitation., Results: Forty-one patients, 61% female, age 60 ±18 yr were included between March 2010 and May 2019. No major adverse events or deaths related to progression of right-sided heart failure were reported. Nevertheless, 22% of participants suffered adverse events in most cases not linked with physical activity. Rehabilitation as add-on to medical therapy and/or arterial deobstruction improved New York Heart Association class: mean difference, -0.39 (95% CI, -0.68 to -0.10), 6-min walk test: mean difference, 80 m (95% CI, 46-114), and was associated with improved right-sided heart hemodynamics. The risk assessment grade improved by -0.25 points (95% CI, -0.44 to -0.06) after rehabilitation., Conclusions: For patients with PAH or CTEPH, supervised rehabilitation as add-on to medical therapy and/or arterial deobstruction is safe and effective in improving patient and clinically related outcomes., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results